Impact of a Specialty Pharmacy-Based Oral Chemotherapy Adherence Program on Patient Adherence
Class of 2016 Abstract === Objectives: Patient medication adherence is a basic requirement for treating chronic myelogenous leukemia (CML) with oral tyrosine kinase inhibitors (TKIs). When imatinib adherence rates are less than 80 or 90 percent, major and complete molecular responses, respectively,...
| Main Authors: | , , , |
|---|---|
| Language: | en_US |
| Published: |
The University of Arizona.
2016
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/614015 http://arizona.openrepository.com/arizona/handle/10150/614015 |